Nabla Bio

Nabla Bio is dedicated to empowering pharmaceutical and biotechnology companies in their efforts to deliver a greater number of effective antibody therapies to patients. By leveraging the power of artificial intelligence in conjunction with massively parallel experimentation, Nabla Bio designs antibodies with pinpoint accuracy, ensuring they bind to the intended disease target at the optimal location. This approach simultaneously minimizes potential risks related to manufacturability and toxicity. As a well-funded and revenue-generating company, Nabla Bio operates bilingually, bringing together a diverse team of both wet-lab and dry-lab scientists. The company was founded by leading AI and protein design experts from Harvard University, ensuring a strong foundation in cutting-edge research and development.